Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

@article{Seront2012PhaseIS,
  title={Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.},
  author={Emmanuel Seront and Sylvie Rottey and Brieuc Sautois and Joseph N. Kerger and Lionel d'Hondt and Vincent Verschaeve and J Ca{\~n}{\'o}n and Catherine Dopchie and J M Vandenbulcke and Nicolas Whenham and Jean Charles Goeminne and Marylene Clausse and Didier Verhoeven and Philippe Glorieux and S Branders and Pierre Dupont and Joelle Schoonjans and Olivier Feron and Jean-Pascal Machiels},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 10},
  pages={2663-70}
}
BACKGROUND This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. PATIENTS AND METHODS Thirty-seven patients with advanced TCC received everolimus 10 mg/day until progressive disease (PD) or unacceptable toxicity. The primary end point was the disease control rate (DCR), defined as either stable disease (SD), partial response (PR), or complete… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia • 2018

Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.

Methods in molecular biology • 2018
View 2 Excerpts

Similar Papers

Loading similar papers…